Characterization of muscle strength and mobility in oculopharyngeal muscular dystrophy.
dynamometry
functional performance outcomes
mobility capacities
neuromuscular disease
strength
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
13
09
2023
received:
27
07
2022
accepted:
19
09
2023
medline:
22
11
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Muscle weakness, and its association with mobility limitations, has received little study in oculopharyngeal muscular dystrophy (OPMD) using quantitative and standardized assessments. The objectives of this study were to (1) document upper and lower limb muscle strength, upper limb functions, fatigue, and mobility capacities; (2) compare them with reference values and across participant age groups; and (3) explore associations between muscle strength, fatigue, and mobility capacities among adults with OPMD. Thirty-four participants were included in this cross-sectional study. The following variables were assessed: quantitative maximal isometric muscle strength, grip and pinch strength, fatigue, walking speed, walking endurance, sit-to-stand, and stair ascent and descent capacities. Muscle strength was lower for older than younger participants for five muscle groups (P < .05). Walking endurance, sit-to-stand, stairs (ascent and descent), and strength of hip flexion, grip, and pinch were below 80% of reference values in participants ≥56 y old (55.3%-78.2%). Moderate to strong correlations were found between muscle strength and mobility capacities (ρ = 0.42-0.80, P < .05), and between fatigue and either muscle strength or mobility capacities (ρ = 0.42-0.75, P < .05). This study highlights the impact of OPMD on strength, endurance, and functional capacity, among others, with patients being well below reference values even before the age of 65 y. In addition to helping health professionals to offer better clinical guidance, these results will improve clinical trial readiness. The next steps will be to assess the metrological properties of outcome measures and continue to document the disease progression rate.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-849Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : career-grant funding for C.G. (no. 31011)
Organisme : Programme de soutien au développement de la mission universitaire of the Centre intégré universitaire de santé et de services sociaux du Saguenay - Lac-St-Jean
Informations de copyright
© 2023 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.
Références
Robinson DO, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet. 2005;116(4):267-271.
Brisson JD, Gagnon C, Brais B, Côté I, Mathieu J. A study of impairments in oculopharyngeal muscular dystrophy. Muscle Nerve. 2020;62(2):201-207.
Tondo M, Gamez J, Gutierrez-Rivas E, Medel-Jimenez R, Martorell L. Genotype and phenotype study of 34 Spanish patients diagnosed with oculopharyngeal muscular dystrophy. J Neurol. 2012;259(8):1546-1552.
van der Sluijs BM, van Engelen BG, Hoefsloot LH. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene. Hum Mutat. 2003;21(5):553.
van der Sluijs BM, Lassche S, Knuiman GJ, et al. Involvement of pelvic girdle and proximal leg muscles in early oculopharyngeal muscular dystrophy. Neuromuscul Disord. 2017;27(12):1099-1105.
Youssof S, Schrader R, Bear D, Morrison L. Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: a retrospective study with implications for trial design. Neuromuscul Disord. 2015;25(3):238-246.
Youssof S. The relationship between physical symptoms and health-related quality of life in oculopharyngeal muscular dystrophy. Muscle Nerve. 2016;53(5):694-699.
van der Sluijs BM, Knoop H, Bleijenberg G, van Engelen BG, Voermans NC. The Dutch patients' perspective on oculopharyngeal muscular dystrophy: a questionnaire study on fatigue, pain and impairments. Neuromuscul Disord. 2016;26(3):221-226.
Fernandez M, Youssof S. Reliability and validity of the 6-minute walk test as an outcome measure in oculopharyngeal muscular dystrophy. Carmel, California. J Investig Med. 2016;64(1):344-345.
Witting N, Mensah A, Køber L, et al. Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurol Scand. 2014;130(2):125-130.
Kroon R, Kalf JG, de Swart BJM, et al. Longitudinal assessment of strength, functional capacity, oropharyngeal function, and quality of life in Oculopharyngeal muscular dystrophy. Neurology. 2021;97(15):e1475-e1483.
Floyd R, Thompson C. Manual of Structural Kinesiology. McGraw-Hill Education; 2011.
Petitclerc E, Hebert LJ, Mathieu J, Desrosiers J, Gagnon C. Lower limb muscle strength impairment in late-onset and adult myotonic dystrophy type 1 phenotypes. Muscle Nerve. 2017;56(1):57-63.
Werle S, Goldhahn J, Drerup S, Simmen BR, Sprott H, Herren DB. Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg Eur. 2009;34(1):76-84.
Bohannon RW, Williams AA. Normal walking speed: a descriptive meta-analysis. Physiotherapy. 2011;97(3):182-189.
American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
Stratford P, Binkley J, Stratford D. Development and initial validation of the upper extremity functional index. Physiother Can. 2001;53(4):259-267.
Worm-Smeitink M, Gielissen M, Bloot L, et al. The assessment of fatigue: psychometric qualities and norms for the checklist individual strength. J Psychosom Res. 2017;98:40-46.
McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017;88(16):1512-1519.
Nightingale EJ, Pourkazemi F, Hiller CE. Systematic review of timed stair tests. J Rehabil Res Dev. 2014;51(3):335-350.
Hogrel JY, Payan CA, Ollivier G, et al. Development of a French isometric strength normative database for adults using quantitative muscle testing. Arch Phys Med Rehabil. 2007;88(10):1289-1297.
Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763-1768.
Laberge AM, Michaud J, Richter A, et al. Population history and its impact on medical genetics in Quebec. Clin Genet. 2005;68(4):287-301.
Raz Y, Raz V. Oculopharyngeal muscular dystrophy as a paradigm for muscle aging. Front Aging Neurosci. 2014;6:317.
Anvar SY, Raz Y, Verway N, et al. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging. Aging (Albany NY). 2013;5(6):412-426.
Richard P, Trollet C, Stojkovic T, et al. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology. 2017;88(4):359-365.